All In Biotech

NDA 013263 · Waylis Therap

Valium

Diazepam · Oral · Benzodiazepine

Novel

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1963

Nov 15, 1963

Approved uses

1

Original approval plus efficacy supplements

Registered trials

118

16 Phase 3, 6 recruiting

FAERS reports

122,026

99,147 serious, 23,313 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions (5.1) , Drug Interactions (7.1) ]. The use of benzodiazepines, including VALIUM, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes....

What it is approved for

From the label in effect Oct 6, 2026.

VALIUM is indicated for the: Treatment of anxiety disorders Short-term treatment of anxiety symptoms Treatment of tremor, acute agitation, hallucinosis, and impending delirium tremens or delirium tremens in acute alcohol withdrawal Adjunctive treatment of skeletal muscle spasm due to: reflex spasm to local pathology spasticity caused by upper motor neuron disorders athetosis stiff-person syndrome Adjunctive treatment of seizure disorders Limitations of Use The effectiveness of VALIUM for long-term use (greater than 4 months) has not been evaluated. VALIUM is not recommended as maintenance monotherapy for the treatment of seizure disorders. VALIUM is a benzodiazepine indicated for the: ( 1 ) Treatment of anxiety disorders Short-term treatment of anxiety symptoms Treatment of tremor, acute agitation, hallucinosis, and impending delirium tremens or delirium tremens in acute alcohol withdrawal Adjunctive treatment of skeletal muscle spasm due to reflex spasm to local pathology, spasticity caused by upper motor neuron disorders, athetosis, or stiff-person syndrome Adjunctive treatment of seizure disorders Limitations of Use The effectiveness of VALIUM for long-term use (greater than 4 months) has not been evaluated ( 1 ) VALIUM is not recommended as maintenance monotherapy for the treatment of seizure disorders ( 1 )

Mechanism: The mechanism of action of diazepam for the listed indications [see Indications and Usage (1) ] is thought to involve potentiation of gamma aminobutyric acid (GABA), an inhibitory neurotransmitter, resulting from binding at the benzodiazepine site of the GABA A receptor.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 15, 1963 Original approval · Type 1 - New Molecular Entity
3 products under this application
  • VALIUM · DIAZEPAM 10MG · TABLET, ORAL · Prescription · TE AB
  • VALIUM · DIAZEPAM 5MG · TABLET, ORAL · Prescription · TE AB
  • VALIUM · DIAZEPAM 2MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Diazepam" as an intervention, any sponsor and status, largest first.

All 118 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • toxicity to various agents9,867
  • drug abuse7,278
  • drug ineffective7,261
  • nausea6,339
  • fatigue5,823
  • pain5,297
  • anxiety5,105
  • somnolence5,104
  • headache5,090
  • off label use4,802
  • dizziness4,588
  • vomiting4,534

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,847
20052,190
20061,948
20072,018
20082,664
20092,807
20103,815
20114,069
20124,881
20135,162
20145,458
20157,240
20167,839
20178,052
20188,633
20199,208
20208,609
20216,932
20226,023
20235,850
20246,079
20256,122
20264,566

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Valium (Diazepam)

2024 spending

$5.6M

Beneficiaries

1,490

7,522 claims

Per beneficiary

$3,773

$10.33 per unit

View as table
YearSpending
2020$6,528,248
2021$5,937,319
2022$4,455,813
2023$4,738,109
2024$5,621,907

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,556 on PubMed

Sponsor: Waylis Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.